“…It has been described that patients with COVID-19 present various alterations, firstly dysgeusia, later hypogeusia, and to a lesser extent ageusia, together with olfactory alterations, hyposmia or anosmia; the only manifestations of COVID-19 infection often presented without concomitant nasopharyngeal symptoms in 95% of the cases [14,26,29,36,37,39,40,41,43,44,48,49,51,54,57,5 9,60,61,66,67,68,70,71,73,74,78,80,82,83,84, 9, 92,94,96,99] and without differences between both genders being observed. In addition, appearing in an early period of the infection, between the second and sixth day after the onset of the first symptom related to COVID-19, they even appear before patients are hospitalized, rapidly worsening [17,18,29,33,60,71,78]. These epithelial and neural disorders could be associated with the direct action of the virus, since patients by referring only dysgeusia or ageusia and the absence of any olfactory disorder could be considered as initial symptoms of the oral manifestations of the COVID-19 [26,40,67] it is therefore of vital importance to evaluate the presence of xerostomia (hyposalivation) or other chemosensory alterations due to the potential invasive and neutrophic properties of the SARS-CoV-2, [26,37,44,45,49,52,61,67,82,83] which could result in a serious respiratory infection since the decrease in salivary secretion alters the surface of the oral mucosa and the respiratory tract as a physical barrier, improving the viral colonization pathway and causing the reduction of many antiviral proteins, by reducing their half-life [40,41,45,48,60,71].…”